Biofrontera Inc. Related Parties Amount in Cost of Sales
Biofrontera Inc. (BFRI) reported Related Parties Amount in Cost of Sales of $16.79 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartiesAmountInCostOfSales · last filed 2024-03-15
- Biofrontera Inc. related parties amount in cost of sales for the quarter ending 2023-12-31 was $4.97M, a 2.72% decline year-over-year.
- Biofrontera Inc. related parties amount in cost of sales for the quarter ending 2023-09-30 was $4.50M, a 111.33% increase year-over-year.
- Biofrontera Inc. related parties amount in cost of sales for the quarter ending 2023-06-30 was $2.77M, a 15.40% increase year-over-year.
- Biofrontera Inc. related parties amount in cost of sales for the quarter ending 2023-03-31 was $4.55M, a 8.60% decline year-over-year.
- Biofrontera Inc. related parties amount in cost of sales for fiscal 2023 was $16.79M, a 14.85% increase from fiscal 2022.
- Biofrontera Inc. related parties amount in cost of sales for fiscal 2022 was $14.62M, a 19.60% increase from fiscal 2021.
- Biofrontera Inc. related parties amount in cost of sales for fiscal 2021 was $12.22M, a 47.02% increase from fiscal 2020.
- Biofrontera Inc. related parties amount in cost of sales for fiscal 2020 was $8.31M.
| Period end | Related Parties Amount in Cost of Sales 3 month | Related Parties Amount in Cost of Sales 6 month | Related Parties Amount in Cost of Sales 9 month | Related Parties Amount in Cost of Sales 12 month |
|---|---|---|---|---|
| 2023-12-31 | $4.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $9.47M derived: sum of 2 quarters · filed 2024-03-15 | $12.24M derived: sum of 3 quarters · filed 2024-03-15 | $16.79M 10-K · filed 2024-03-15 |
| 2023-09-30 | $4.50M 10-Q · filed 2023-11-09 | $7.27M derived: sum of 2 quarters · filed 2023-11-09 | $11.81M 10-Q · filed 2023-11-09 | $16.93M derived: sum of 4 quarters · filed 2024-03-15 |
| 2023-06-30 | $2.77M 10-Q · filed 2023-08-11 | $7.32M 10-Q · filed 2023-08-11 | $12.43M derived: sum of 3 quarters · filed 2024-03-15 | $14.56M derived: sum of 4 quarters · filed 2024-03-15 |
| 2023-03-31 | $4.55M 10-Q · filed 2023-05-12 | $9.66M derived: sum of 2 quarters · filed 2024-03-15 | $11.79M derived: sum of 3 quarters · filed 2024-03-15 | $14.19M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-12-31 | $5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $7.24M derived: sum of 2 quarters · filed 2024-03-15 | $9.64M derived: sum of 3 quarters · filed 2024-03-15 | $14.62M 10-K · filed 2024-03-15 |
| 2022-09-30 | $2.13M 10-Q · filed 2023-11-09 | $4.53M derived: sum of 2 quarters · filed 2023-11-09 | $9.50M 10-Q · filed 2023-11-09 | $14.10M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.40M 10-Q · filed 2023-08-11 | $7.38M 10-Q · filed 2023-08-11 | $11.97M derived: sum of 3 quarters · filed 2023-08-11 | $14.22M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $4.97M 10-Q · filed 2023-05-12 | $9.57M derived: sum of 2 quarters · filed 2023-05-12 | $11.82M derived: sum of 3 quarters · filed 2023-05-12 | $14.79M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $6.84M derived: sum of 2 quarters · filed 2023-03-13 | $9.81M derived: sum of 3 quarters · filed 2023-03-13 | $12.22M 10-K · filed 2023-03-13 |
| 2021-09-30 | $2.25M 10-Q · filed 2022-11-14 | $5.22M derived: sum of 2 quarters · filed 2022-11-14 | $7.63M 10-Q · filed 2022-11-14 | $11.92M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.97M 10-Q · filed 2022-08-12 | $5.38M 10-Q · filed 2022-08-12 | $9.67M derived: sum of 3 quarters · filed 2022-08-12 | $10.24M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $2.41M 10-Q · filed 2022-05-13 | $6.70M derived: sum of 2 quarters · filed 2022-05-13 | $7.26M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-11 | $4.86M derived: sum of 2 quarters · filed 2022-04-11 | $8.31M 10-K · filed 2022-04-11 | |
| 2020-09-30 | $567.00K 10-Q · filed 2021-11-30 | $4.03M 10-Q · filed 2021-11-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |